智联招聘数据显示，2025年四季度，高端装备领域中，机器人行业招聘职位数同比增长37.3%；人工智 能行业在新一代信息技术领域增速最快，同比增长19.0%，智能硬件行业增长11.5%；生物制造领域体 外诊断行业增长14.2%。新兴产业蓬勃发展，带来高技术岗位扩容、薪酬水平提升、技能要求升级。 "管产业就要管就业、促消费就要促就业、上项目就要扩就业"，这一"大就业观"成为宏观调控优先目 标，推动经济社会协调发展。2025年7月，围绕稳就业、稳企业、稳市场、稳预期，《国务院办公厅关 于进一步加大稳就业政策支持力度的通知》从支持企业稳岗、激励扩岗吸纳、强化技能培训等7个方面 出台政策举措，全力稳住就业基本盘。 各地紧盯重点群体就业需求，持续拓宽重点行业就业渠道，大力培育新产业新业态带动就业增长，充分 发挥重大项目吸纳就业作用，不断强化民生领域就业服务支撑，多举措稳定和扩大就业岗位。 真金白银投入，为稳就业提供有力支撑。2025年，全国支出就业补助资金超1000亿元，失业保险降费率 为企业减负1872亿元，发放稳岗返还资金336亿元，为企业纾困解难。金融支持稳岗扩岗力度持续加 大，支持对象覆盖个人，企业最高授信额度提 ...

报告期内，公司对联营企业舜景医药增资，舜景医药成为公司的控股子公司，并按同一控制下的企业合 并纳入了合并报表；2025年度舜景医药创新药管线的研发和临床进程的持续推进，研发投入7,861.68万 元。 报告期内，公司联营企业尧景基因、智源生物等持续加大在生物创新药等领域的研发投入，导致公司确 认对联营企业的投资损失1,351.40万元。 报告期内，公司所处体外诊断行业受集采等行业政策影响，短期国内价格下降及需求减少，叠加国家对 本行业税收政策调整，导致营业收入下降10,320.62万元；另一方面，公司按照一贯的计提减值政策进行 测算，对与此相关的试剂和设备等经营资产计提3,801.22万元减值损失。 智通财经APP讯，热景生物(688068.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 40,769.38万元，与去年同期相比下降20.20%；实现归属于母公司所有者的净利润-21,051.69万元，实现 归属于母公司所有者的扣除非经常性损益的净利润-25,811.46万元。 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to industry policy impacts and increased competition in the in vitro diagnostics sector [1] Financial Performance - The company achieved an operating revenue of 407.69 million yuan, a decrease of 20.20% compared to the same period last year [1] - The net profit attributable to the parent company was -210.52 million yuan, with a net profit excluding non-recurring gains and losses of -258.11 million yuan [1] Industry Impact - The in vitro diagnostics industry faced challenges from centralized procurement policies, leading to a short-term decline in domestic prices and reduced demand, contributing to a revenue drop of 103.21 million yuan [1] - Changes in national tax policies for the industry also negatively affected revenue [1] Asset Impairment - The company recognized an impairment loss of 38.01 million yuan on related operating assets, including reagents and equipment, following its consistent impairment policy [1] Investments and R&D - The company increased its investment in the joint venture ShunJing Pharmaceutical, which became a subsidiary and was included in the consolidated financial statements [1] - ShunJing Pharmaceutical continued to advance its innovative drug pipeline, with R&D expenditures amounting to 78.62 million yuan during the reporting period [1] - The company also reported investment losses of 13.51 million yuan from joint ventures such as YaoJing Gene and ZhiYuan Bio, which increased their R&D investments in the field of biopharmaceuticals [1]

证券之星消息，浩欧博近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润盈利0.234 亿元，同比减少36.37%。 业绩快报公告中对经营业绩和财务状况情况的说明： （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 报告期内公司实现营业收入 39,839.98 万元，较上年同期下降 0.98%；实现营业利润 2,666.35 万元，较 上年同期下降 35.57%；实现归属于母公司所有者的净利润 2,341.81 万元，较上年同期下降 36.37%；实 现归属于母公司所有者的扣除非经常性损益的净利润 1,494.03 万元，较上年同期下降 58.36%。 （二）上表中有关项目增减变动幅度达 30%以上的主要原因说明 报告期内，公司营业利润、利润总额、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经 常性损益的净利润、基本每股收益下降的主要原因如下： 1、受宏观市场环境及相关政策调整影响，公司整体销售规模略有下滑，对营业收入、净利润等财务指 标构成一定影响。 2、受自动化仪器投放规模扩大及募投项目新建大楼投入使用影响，公司资产折旧费用增加，整体成本 总额有所上升；同时 ...

机构持仓方面，截止2025年9月30日，九强生物十大流通股东中，华宝中证医疗ETF（512170）位居第 八大流通股东，持股834.46万股，相比上期减少140.85万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，北京九强生物技术股份有限公司位于北京市海淀区花园东路15号旷怡大厦5层，成立日期 2001年3月29日，上市日期2014年10月30日，公司主营业务涉及一家以生化诊断、血凝检测、血型检测 和肿瘤病理检测的研发、生产和销售。主营业务收入构成为：体外检测试剂95.09%，体外检测仪器 3.06%，其他业务收入0.96%，检验服务0.53%，仪器租赁收入0.36%。 截至9月30日，九强生物股东户数1.81万，较上期减少2.48%；人均流通股23502股，较上期增加2.54%。 2025年1月-9月，九强生物实现营业收入10.12亿元，同比减少18.24%；归母净利润2.72亿元，同比减少 2 ...

Group 1: Project Acceleration and Industrial Development - Key projects are identified as the "lifeline" for industrial development, with a focus on the construction of the Chip Industry Base, Haibo Hotel, and Meiteng Technology Phase II, emphasizing a sense of urgency in project execution [2] - Tianjin Chip Technology Co., Ltd. is investing 290 million yuan in a photonics industry base, with a total construction area of nearly 50,000 square meters, set to enter the main construction phase soon and expected to be completed by October this year [3] - The project aims to achieve an annual production capacity of 80,000 photonic chips and 120,000 photonic devices, with an anticipated annual output value of 1.5 billion yuan [3] Group 2: Market Expansion and Technological Innovation - Danna Biotechnology, a leader in the in vitro diagnostic industry, has successfully secured numerous overseas orders from countries including Germany and Ethiopia, showcasing its strong international market presence [4] - The company has received 102 EU CE certifications for its products, which are sold in over 90 countries, highlighting its commitment to technological innovation and quality [4] - Danna Biotechnology has led over 20 national and Tianjin municipal major science and technology projects, accumulating 91 authorized patents, which supports its high-quality development and international expansion [4] Group 3: Cultural and Creative Industry Innovation - The National Animation Park and Haochuan Animation have launched a cultural digital experience center, which has attracted significant visitor interest during the Spring Festival, showcasing the integration of cultural content and consumer experience [5][6] - The experience center features popular IPs and aims to create an immersive environment that combines cultural resonance with interactive experiences, reflecting the vitality of the domestic animation industry [5][6] - Haochuan Animation is actively developing new IPs and optimizing existing works, demonstrating its commitment to innovation in the cultural and creative sector [6] Group 4: Overall Development Strategy - The Tianjin Eco-City is focused on high-quality development by accelerating project construction, expanding market opportunities, and fostering innovation in the cultural sector [6] - The Eco-City aims to leverage the opportunities presented by the Beijing-Tianjin-Hebei coordinated development strategy and actively integrate into the modern capital metropolitan area [6] - The initiative seeks to attract more quality resources, enterprises, and projects to enhance corporate development and stimulate innovation, contributing to the establishment of a national green development demonstration zone [6]

Core Viewpoint - The company Aihuilong is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements, marking a significant shift in regulatory scrutiny within the capital market [1][5][16]. Group 1: Company Background - Aihuilong, a star listed company on the Sci-Tech Innovation Board, was founded by Hu De Ming in 2008 and has been led by his son, Hu Kunhui, since 2012 [9][10]. - The company gained prominence during the COVID-19 pandemic, achieving a revenue of 39.81 billion yuan and a net profit of 10.22 billion yuan in 2022, but has since faced a significant decline in performance [12][13]. Group 2: Recent Events - Aihuilong held a celebratory annual meeting on February 3, 2026, shortly before the CSRC announced the investigation on February 6, highlighting a stark contrast between the company's optimistic public image and its regulatory challenges [2][5][4]. - Following the announcement of the investigation, Aihuilong's stock price plummeted to a historical low of 13.53 yuan, representing a 69.9% decrease in market value since its IPO [5][12]. Group 3: Regulatory Environment - The CSRC's investigation into Aihuilong is part of a broader trend of intensified regulatory scrutiny in the Chinese capital market, with an average of one company being investigated every five days since the beginning of 2026 [1][16]. - The regulatory response to Aihuilong's misleading announcement regarding a partnership in brain-computer interface technology reflects a zero-tolerance approach to information disclosure violations [6][17]. Group 4: Financial Performance - Aihuilong's financial performance has deteriorated sharply, with a projected net profit drop of 90.05% to 93.37% for 2025, attributed to a decline in COVID-related business and market demand [12][13]. - The company's international business has shown some growth, with overseas revenue reaching 2.08 billion yuan in the first three quarters of 2025, a 39.39% increase year-on-year [12].

截至2月11日，2026年开年以来，平均不足5天即有一家上市公司被立案，不足3天即有一家受罚。这标 志着以"零容忍"为基调、贯穿"事前-事中-事后"的全链条监管新常态已确立，正以从严从快的系统性工 程，持续推动中国资本市场生态重塑。 导读： 2026年2月6日，亚辉龙因"公告涉嫌误导性陈述"被证监会立案调查。三天前，公司年会举行，管理层指 明发展方向，《骄傲的少年》歌声刚落，金色标语"龙腾万里志，马跃新征程"高悬在宴会厅中。 亚辉龙董事长、CEO胡鹍辉是90后少帅，频繁以"海归精英""青年旗手"形象亮相，21岁时因父亲涉诉继 承家族企业，在2021年带领公司登陆科创板。2024年10月，胡鹍辉以60亿元人民币财富位列《2024年· 胡润百富榜》第875位。 这样一家明星上市科创企业，欢声笑语中被迎头浇了一盆冷水，这既是证券市场常态化严格监管的一个 缩影，也体现出监管层对相关违规公司"戒骄戒躁"的劝诫。 暴风雨来临前的盛典 2026年2月3日晚7点，位于深圳龙岗的亚辉龙总部宴会厅内灯火通明。歌舞升平、觥筹交错之间，一派 热烈的年会盛典气氛正被推向顶点，这与公司长期低迷股价形成微妙对比。 董事长兼CEO胡鹍辉立于 ...

Core Viewpoint - Innotech (688253) reported a decline in both revenue and net profit for the year 2025, while also announcing progress in new business and product developments [1] Business Performance - Innotech achieved an operating revenue of 422 million yuan in 2025, a year-on-year decrease of 32.08% - The net profit attributable to shareholders was 146 million yuan, down 40.84% year-on-year - The fluctuations in performance were primarily influenced by policy adjustments in the in vitro diagnostics industry, intensified competition in the respiratory testing sector, and a weaker flu season compared to the previous year [2] Business Progress - The company disclosed that its first single-molecule detection instrument and reagents for neurological testing have obtained product registration certificates - New registrations were also achieved in the international market, including EU IVDR and US FDA certifications - Collaborations with platforms like JD.com and Meituan are enhancing the brand building for home testing, which is expected to be a focal point for future business expansion [3] Company Status - From November 18 to December 1, 2025, Innotech conducted a shareholder reward activity, providing prizes to stockholders, reflecting the company's efforts to maintain shareholder relations [4]

Company Fundamentals - The company is expected to report a net loss of between 25 million to 36 million yuan for the year 2025, marking its first loss since going public [1] - The third-quarter financial report indicated a year-on-year revenue decline of 22.8% and a net profit drop of 146.65%, with gross margin decreasing to 15.84%, reflecting deteriorating profitability [1] Contract Developments - In January 2026, the company signed an 8-year procurement agreement worth no less than 600 million yuan with Nanjing Mingji Hospital and Suzhou Mingji Hospital, but the annual procurement amount is expected to be less than 10% of the company's annual revenue, limiting its short-term impact on performance [2] - The Shanghai Stock Exchange issued a regulatory letter questioning the commercial rationale of the agreement and the substantive constraints of the minimum procurement amount, raising concerns about long-term performance risks [2] Financial Condition - As of February 13, 2026, the company's price-to-earnings ratio (TTM) stands at -577.56 times, and the price-to-book ratio is 5.94 times, indicating a severe disconnect between valuation and profitability [3] - By the end of the third quarter of 2025, the company's cash reserves were only 120 million yuan, a 40% decrease from 2023, while accounts receivable accounted for 138.8% of revenue, indicating significant pressure on cash flow [3] Stock Price Situation - The stock price has fallen nearly 40% from its peak in December 2025, with recent moving averages showing a bearish trend; on February 13, there was a net outflow of 300,400 yuan in principal funds, reflecting a pessimistic market sentiment [4] - On February 6, the stock was placed on the "Dragon and Tiger List" due to a price deviation of 7%, with institutional funds showing concentrated outflows, indicating a risk-averse tendency among investors [4] - The stock price reaching a 60-day low is attributed to a combination of performance losses, policy impacts, valuation bubbles, and cash flow pressures [4]